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Abstract
Background—Epidemiological studies demonstrate that childhood infections, including 
varicella zoster virus (VZV), are associated with an increased risk of arterial ischemic stroke 
(AIS). Other herpesviruses have been linked to childhood AIS in case reports. We sought to 
determine whether herpesvirus infections, which are potentially treatable, increase risk of 
childhood AIS.
Methods and Results—We enrolled 326 centrally-confirmed cases of AIS and 115 stroke-free 
controls with trauma (ages 29 days-18 years) with acute blood samples (≤3 weeks after stroke/
trauma); cases had convalescent samples (7-28 days later) when feasible. Samples were tested by 
commercial ELISA kits for IgM/IgG antibodies to herpes simplex virus (HSV) 1 and 2, 
cytomegalovirus (CMV), Epstein Barr virus (EBV), and varicella zoster virus (VZV). An 
algorithm developed a priori classified serologic evidence of past and acute herpesvirus infection 
as dichotomous variables. Median (quartiles) age was 7.7 (3.1-14.3) years for cases and 10.7 
(6.9-13.2) for controls (p=0.03). Serologic evidence of past infection did not differ between cases 
and controls. However, serologic evidence of acute herpesvirus infection doubled the odds of 
childhood AIS, even after adjusting for age, race, and socio-economic status (OR 2.2; 95% 
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confidence interval, 1.2-4.0; p=0.007). Among 187 cases with acute and convalescent blood 
samples, 85 (45%) showed evidence of acute herpesvirus infection, with HSV-1 found most often. 
Most infections were asymptomatic.
Conclusions—Herpesviruses may act as a trigger for childhood AIS, even if the infection is 
subclinical. Antivirals like acyclovir might have a role in the prevention of recurrent stroke if 
further studies confirm a causal relationship.
Keywords
ischemic stroke; infection; vaccination; children; pediatric
INTRODUCTION
Arterial ischemic stroke (AIS) affects at least 2.4 per 100,000 US children every year,1, 2 
with a high burden of long-term morbidity among survivors.3 The causes of childhood AIS 
are heterogeneous, and many cases remain idiopathic; established adult stroke risk factors 
are rarely present. Etiologies include certain chronic conditions, such as congenital heart 
disease and sickle cell disease, as well as acute disorders, such as arterial dissection and 
transient cerebral arteriopathy. Acute precipitants of stroke among children with chronic risk 
factors, as well as precipitants of acute arteriopathies, remain uncertain. Understanding the 
acute triggers of childhood AIS, and how they relate to chronic risk factors, will help guide 
strategies for prevention.
While severe infections such as meningitis and endocarditis have long been linked to risk of 
AIS in adults and children, more recent studies provide evidence for minor clinical 
infections, such as the common cold, as a trigger for stroke.4–8 Infection could predispose to 
stroke through systemic inflammation causing a transient hypercoagulable state or 
endothelial injury. VZV, a member of the herpesvirus family, has been linked to AIS via a 
much more specific mechanism: by infecting the trigeminal nerve, which provides 
innervation to the cerebral vasculature, the virus may directly invade vessel walls and cause 
a focal arteriopathy (“post-varicella arteriopathy”).9–15 In a recent self-controlled case series 
analysis, children had a four-fold increased risk of receiving a stroke diagnosis in the six 
months after a chickenpox diagnosis.16 The median time from clinical VZV infection to 
stroke was 18 weeks in a systematic review of the literature.17 Existing data on the role of 
VZV in childhood AIS have, however, been limited by single-center design, recall bias in 
ascertainment of infections, absence of standardized assessment of herpes infections, or 
small numbers of cases, particularly for children. Data on other herpesviruses (HSV1, EBV) 
and childhood arteriopathy and AIS are limited to case reports.18–20 A link between other 
herpesviruses (HSV1, HSV2, EBV, CMV) and atherosclerosis and stroke in adults has also 
been postulated, but never well established.18, 21–25 Because herpesvirus infections are 
treatable with antivirals like acyclovir, evidence supporting a role in stroke pathogenesis 
would have important implications for stroke prevention therapies. More than one in ten 
children with AIS will suffer a recurrence,26, 27 indicating an urgent need for better 
secondary stroke prevention strategies.
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We therefore assessed the association between serological evidence of past and acute 
herpesvirus infection and childhood AIS by performing an international, prospective, case-
control study: the Vascular effects of Infection in Pediatric Stroke (VIPS) study. We 
hypothesized that serological evidence of acute herpesvirus infection (VZV, HSV1, HSV2, 
EBV, CMV) would be associated with risk of AIS among children ages 29 days to 18 years 
compared to an unmatched population of pediatric controls who had blood drawn while 
being evaluated for traumatic injury.
METHODS
Setting and Case Enrollment
Between 1/2010 and 3/2014, VIPS prospectively enrolled cases of childhood AIS and 
stroke-free controls at 37 International Pediatric Stroke Study (IPSS) centers in 9 countries: 
US, Canada, Australia, Philippines, Chile, United Kingdom, France, Serbia, and China 
(Figure). Ethics approvals were obtained at the lead institutions (University of California, 
San Francisco [UCSF], and Hospital for Sick Children, Toronto) and each enrolling site. 
Details of case ascertainment, confirmation, imaging review, laboratory analyses, and 
clinical data collection are published in the VIPS methods paper.28 In brief, case inclusion 
criteria were age 29 days through 18 years at the time of AIS, clinical and imaging evidence 
of AIS, minimum neuroimaging performed including cerebrovascular imaging, enrollment 
within three weeks of stroke ictus (a change from two weeks in the published methods), and 
parental or other legal guardian consent (and patient assent, when appropriate) to 
participation in the study. Site investigators and/or their local research staff abstracted data 
from medical records regarding stroke presentation, risk factors, etiologic investigation, and 
treatment, and mailed neuroimaging studies to the imaging core at UCSF. This analysis was 
limited to the 326 cases and 115 controls with adequate blood samples (Figure).
Case Confirmation and Classification of Stroke Subtype
A neuroradiologist and pediatric stroke neurologist performed centralized review of brain 
parenchymal imaging and clinical data to confirm that cases met pre-established clinical and 
imaging criteria for AIS in children: “a focal neurological deficit of acute onset or a 
seizure,” and “a focal brain infarct conforming to an established arterial territory in a 
location and of a maturity consistent with the neurological signs and symptoms.”28 
Discordant opinions were adjudicated by a second neuroradiologist. Cases were excluded if 
the central review team agreed that either the clinical or imaging criteria had not been met. 
All cases were subjected to a rigorous, multi-step process for classifying stroke subtype, as 
previously described.29 Subtypes of stroke included: arteriopathic (definite or possible), 
cardioembolic, presumed embolic with hypercoagulable condition, other etiology, and 
idiopathic.
Control Enrollment
VIPS enrolled stroke-free unmatched controls aged 29 days through 18 years. Inclusion 
criteria were aimed at selecting children who were comparable to the cases in terms of their 
likelihood of having had a recent infection. VIPS had two types of controls: “routine-visit” 
controls enrolled at the time of a routinely scheduled clinic visit; and “trauma-visit” controls 
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enrolled at the time of an acute care visit or admission for trauma. Only the trauma controls 
could feasibly be consented for a blood sample (at the time of clinical phlebotomy or IV 
insertion), and therefore are the only controls used in the present analysis. The enrollment 
target was 120 trauma controls based on a priori power calculations. Although trauma 
controls were not matched, similar age and geographic distributions were encouraged by 
providing histograms of these characteristics to the sites throughout the enrollment period. 
However, sites that did not commonly care for pediatric trauma patients could not feasibly 
enroll trauma controls.
Parental Interview
To measure clinical history of infection, parents/guardians of both cases and controls 
participated in structured interviews.8, 28 They were asked whether the child had had a 
clinical infection in the 6 months preceding the stroke (cases) or enrollment (controls), and 
were asked detailed questions about the most recent infection including its location, clinical 
manifestations, and severity. They were also asked about prior vaccinations, including VZV, 
and markers of socioeconomic status (SES): residence (urban, suburban, rural), maternal 
education, and household income (converted to US dollars).
Blood Specimen Collection and Laboratory Assays
For ethical reasons, all blood samples were collected at the time of venous or arterial access 
for clinical purposes. For both cases and controls, an acute blood sample (approximately 16 
mL: 10 mL for serum and 6 mL for plasma in ethylenediaminetetraacetic acid) was collected 
as soon as possible after enrollment, or a maximum of three weeks after the stroke ictus in 
cases. Exact volumes varied slightly by patient size and individual site institutional review 
board requirements regarding collection of blood in children. In some cases, blood was 
drawn on separate successive days to comply with algorithms for pediatric phlebotomy. 
Convalescent serum and plasma samples were collected seven to 28 days after the initial 
sample collection when feasible (i.e., when the patient underwent repeat venous or arterial 
access for clinical purposes within that time window). Convalescent samples could not be 
feasibly obtained on the controls. Blood samples were centrifuged, aliquotted, and frozen at 
–70° C at the enrolling site. Samples were then shipped up to twice yearly on dry ice to the 
core laboratory at the Center for Advanced Laboratory Medicine (CALM) at Columbia 
University for storage and batched analysis.
Serological assays for HSV 1, HSV 2, VZV, CMV, and EBV were performed using enzyme 
linked immunosorbent assays (ELISA; Detailed Methods in Supplemental Material). Both 
IgM and IgG serologies were performed on acute and, where available, convalescent 
samples. The commercial ELISA kit for VZV may not detect IgG antibody following 
varicella vaccination.30
Data Analysis and Definitions of Past and Acute Herpesvirus Infection
Baseline characteristics of cases and controls, and of cases with and without paired (acute 
and convalescent) blood samples, were compared using Wilcoxon rank sum tests for 
continuous variables and chi-square tests (or Fisher’s exact, when appropriate) for 
categorical variables. The detailed algorithms for defining serologic evidence of herpesvirus 
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infection were established a priori (Supplemental Tables 1 and 2). Serological evidence of 
past infection was defined as a positive IgG titer (≥1.1) with a negative IgM titer (<1.1) 
Serological evidence of acute infection was defined by either positive IgM titers (≥1.1) or, 
when paired samples were available, by rising IgG titers.
Because convalescent blood samples were not available in controls, all case-control analyses 
defined herpesvirus infection solely on the basis of the acute blood samples (Figure). For 
these analyses, we used logistic regression techniques to construct univariate and 
multivariable models. HSV1 is more common in lower socioeconomic countries, and among 
lower socioeconomic groups within a country.31, 32 Hence, countries where patients were 
enrolled were categorized as either lower and middle income (LAMI) countries, including 
the Philippines, Serbia, and China, or high income countries (all others), as defined by the 
World Bank in 2014.33 In our final multivariable model, we adjusted for individual-level 
SES (collected in the parental interview) and for race because of previously reported racial 
differences in childhood stroke risk.34 We also adjusted for LAMI status, although its 
estimated odds ratio is imprecise due to the small number of controls enrolled in LAMI 
countries. In addition, because controls were enrolled predominantly in the USA, Canada, 
and Chile, we performed sensitivity analyses in which we included only cases and controls 
enrolled in those three countries.
An algorithm using paired blood samples to measure acute herpesvirus infection is 
inherently more sensitive than one using a single acute blood sample. We measured the 
sensitivity (and specificity) of the single-sample algorithm within the subset of cases with 
paired samples, using the paired-sample algorithm as the gold standard. After demonstrating 
low sensitivity (and hence high false negative rate) for the single-sample algorithm, we 
included only cases with paired samples in all case-specific analyses, such as analyses of 
stroke characteristics and parental report of clinical infections preceding the stroke.
Because herpesviruses establish lifelong latency in humans, serologic evidence of acute 
herpesvirus infection could represent either a primary infection (i.e., first infection in a 
susceptible, seronegative individual) or a recurrent infection (i.e., reactivation of a latent 
infection). IgG antibodies are negative at the time of a primary infection, become detectable 
within 2 weeks to 3 months, and then remain elevated indefinitely.35 Among cases with 
paired samples and serologic evidence of acute herpesvirus infection, we defined “serologies 
consistent with primary infection” as either positive IgM antibodies with negative acute IgG 
antibody titers, or rapidly-rising IgG antibody titers (4-fold rise). Because of our wide time 
window for acute blood sample collection (up to 3 weeks after stroke ictus), children with 
positive IgM and IgG antibody titers could have either late primary infection (blood sample 
drawn after IgG antibodies being produced) or recurrent infection. Hence, the proportion 
with “serologies consistent with primary infection” is an underestimate of the true 
proportion with primary infection.
All analyses were conducted using Stata v12 (Stata Corp., College Station, TX) with alpha 
set at 0.05. The level of significance used and the p-values are two-sided.
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RESULTS
Description of the cases and controls
The present analysis includes a case-control study of 326 childhood AIS cases and 115 
stroke-free trauma controls, as well as a case-only study of 187 childhood AIS cases for 
whom both acute and convalescent (paired) blood samples were available (Figure). 
Compared to controls, cases were younger and of lower SES; race and ethnicity did not 
differ significantly (Table 1). Stroke co-morbidities and risk factors (derived from chart 
review), presentation, and infarct characteristics have been published elsewhere.29 
Characteristics of those cases with and without convalescent blood samples are shown in 
Supplemental Table 3. Controls had a variety of traumatic injuries: 42% had a single bone 
fracture; 25% had head or neck injury, 10% had an abdominal injury, and the remainder had 
a variety of injuries, mostly lacerations and dislocations.
Case-Control Analysis: Evidence of past herpesvirus infection
There was no difference between cases and controls in serologic evidence of past 
herpesvirus infection (Table 2). To control for differences in geography, we conducted a 
sensitivity analysis limited to the 275 cases and 114 controls enrolled in the USA, Canada, 
and Chile; the findings were unchanged (Supplemental Table 4). Although commercial VZV 
kits (as used for this study) are insensitive for detecting IgG antibodies after VZV 
vaccination,30 it is possible that some of the positive IgG titers for VZV could be explained 
by prior VZV vaccination: 59.2% of cases and 71.3% of controls had a parental report of 
vaccination against VZV. Excluding children with prior VZV vaccination or unknown VZV 
vaccination status, 43% of 107 cases and 59.3% of 27 controls had positive VZV IgG titers 
(p=0.13).
Case-Control Analysis: Evidence of acute herpesvirus infection
Cases were more likely than controls to have serologic evidence of acute herpesvirus 
infection: 30.1% of cases versus 18.3% of controls had IgM antibody to a herpesvirus (Table 
3). The most prevalent antibodies were for HSV. Of the 80 cases with positive HSV IgM 
antibodies, HSV type could not be determined (based on concomitant IgG antibodies to 
HSV1 and HSV2) in 48 (60%); however, 32 (40%) had evidence of HSV1 infection, and 
none had HSV2.
In our final multivariable model that included other predictors of stroke—residence (urban, 
suburban, rural), age (as a categorical variable), and race—serological evidence of acute 
herpesvirus infection was an independent predictor of stroke risk among children (Table 4); 
the model estimates were similar with and without adjustment for LAMI country status. We 
performed a sensitivity analysis limited to the 275 cases and 114 controls enrolled in the 
USA, Canada, and Chile. There was minimal impact on the model, with an adjusted OR for 
positive acute herpesvirus serologies of 1.8 (95% confidence interval 1.0-3.3, p=0.05, 
without adjustment for LAMI status).
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Prevalence of acute herpesvirus infection among cases with paired samples
Among those with paired samples available for testing, we found that the single-sample 
algorithm, when compared to the gold standard paired-sample algorithm, underestimated the 
actual prevalence of acute herpesvirus infection (Table 5). Although 100% specific, the 
single-sample algorithm had a sensitivity of less than 50% for acute herpesvirus infection 
overall, and approximately 60% for both HSV and VZV. The true prevalence of acute 
herpesvirus infection among childhood AIS cases, based on the paired-sample algorithm, 
could be estimated as 45.5% (85/187). Antibodies against HSV were again the most 
prevalent, identified in75 (88%) of the 85 cases that were positive (Table 5).
Evidence of primary herpesvirus infection
Of the 75 cases with positive acute serologies for HSV, 43 (57%) had either negative IgG or 
a 4-fold rise in IgG titers, suggesting that more than half were primary HSV infections (i.e., 
first-time infection in a seronegative child). Similarly, 5 of 10 with positive acute CMV 
serologies, and 3 of 5 with positive acute EBV serologies, had serologies consistent with 
primary infection. For VZV, on the other hand, the minority (7/18, 39%) had serologies 
consistent with primary infection. As noted in the methods section, these proportions are 
likely underestimates, as children positive for both IgM and IgG could have either late 
primary or recurrent infection.
Clinical and stroke characteristics among cases with evidence of acute herpesvirus 
infection
AIS cases with acute herpesvirus infection were more likely to be from a LAMI country 
than cases without acute herpesvirus infection (Supplemental Table 5). There were no 
differences in stroke subtype (classified on central review), presentation, or infarct 
characteristics. Based on parental interview, only a minority of the 85 children with 
serological evidence of acute herpesvirus infection had a clinical infection in the preceding 
week (17.6%) or month (42.4%). Conversely, acute herpesvirus serologies were positive in 
only 15 (43%) of 35 children with a clinical infection in the prior week, and 36 (46%) of 78 
children with a clinical infection in the prior month. These results suggest that many of the 
clinical infections were not herpesvirus related, and many of the acute herpesvirus infections 
were subclinical.
DISCUSSION
In this international epidemiological study, we found serological evidence that recent, but 
not past, herpesvirus infection is associated with increased risk of AIS among children, even 
after adjusting for age and socioeconomic status. Acute HSV infection was the most 
common, present in 40% of AIS cases; the majority had serologies suggestive of a primary 
HSV infection, as opposed to reactivation of a latent infection. Most of the herpes infections 
were subclinical, and the single acute blood samples had low sensitivity, indicating 
challenges to early diagnosis of a recent herpesvirus infection: clinical history and a single 
set of serologies are not adequate for ruling out infection.
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Other studies of pediatric AIS have found infection to be common prior to stroke. In a prior 
analysis of the VIPS cohort, 39% of cases (versus 22% of controls, p<0.0001) had parental 
report of a clinical infection in the prior 4 weeks, and 18% of cases (3.4% of controls, 
p<0.0001) in the prior 1 week.8 In a retrospective population-based study of children 
enrolled in Kaiser Permanente Northern California, 33% of 126 cases (versus 13% of 
controls) had a medical encounter for infection in the prior 4 weeks,6 and 14% of cases 
(1.7% of controls) had an encounter in the prior 7 days.5 The International Pediatric Stroke 
Study reported preceding infection in 24% of 676 AIS cases enrolled in 10 countries.36 
These studies were primarily based on clinical history of infection, however, and were not 
able to provide serological evidence of infection, nor did they specify types of infections.
Our study provides novel epidemiological evidence that acute herpesvirus infection, in 
particular, may play a role in childhood AIS. Herpesviruses occur worldwide, and are 
unique in that they can establish latency in sensory ganglia or other cells, resulting in a 
lifelong infection.31, 32, 37 Initial infection with HSV, CMV, and EBV is often subclinical. 
All herpesviruses have been implicated in neurological diseases, including meningitis, 
encephalitis, and transverse myelitis. Prior studies of herpesviruses and stroke have focused 
predominantly on VZV. Observational studies provide evidence that children can develop a 
cerebral arteriopathy and AIS after chickenpox.10, 11, 13, 15 Other analyses similarly found 
evidence that VZV is an independent risk factor for stroke in adults <40 years old,38 and that 
some adults with unexplained stroke and arteriopathy have chronic VZV infection.9 
Although adult studies typically sought serological and genomic evidence of VZV in the 
CSF, this was not feasible in VIPS because lumbar puncture is not a routine part of 
childhood stroke evaluation. Nonetheless, our data provide epidemiologic evidence that 
VZV contributes to AIS risk in children.
Our study is the first to address the role of other herpesvirus infections in childhood AIS. In 
fact, we found that positive acute titers for HSV were the most common: among children 
with AIS and paired blood samples, 40% had serologic evidence of acute HSV infection 
(mostly HSV1). The seroprevalence of HSV1 (i.e., prevalence of IgG antibodies indicating 
past infection) increases rapidly with age, reaching 44% in young adults and 90% among 
those >70 years old.31 Published data on acute infection rates with HSV in the general 
population are not available, however. Of note, in our present study, most children with 
serological evidence of acute herpesvirus infection did not have a parental report of recent 
illness, consistent with published serologic studies suggesting that a large proportion of 
herpesvirus infections are subclinical.32
Although causation cannot be inferred from an association in an epidemiological study like 
VIPS, other published studies suggest herpesvirus infections could lead to stroke through 
several different mechanisms, and that these mechanisms may vary by type of herpes virus. 
While infection with VZV is known to directly invade cerebral arteries and cause a focal 
arteritis,9 other herpesvirus infections may have an indirect pathologic effect on arteries by 
causing inflammatory injury to the endothelium. In the late 1970s, herpesviruses were 
demonstrated to induce atherosclerosis-like changes in animal models,39 and HSV has been 
found in early aortic atherosclerotic lesions from humans.40 Herpesviruses cause increased 
expression of cytokines, including interleukin 2 and TNF alpha, as well as vascular smooth 
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muscle cell proliferation and migration.41–43 Our data suggest herpesvirus infection is 
similarly prevalent across pediatric stroke subtypes, including arteriopathic and 
cardioembolic, suggesting a common mechanism. Cardioembolic strokes may be explained 
by inflammatory injury to cardiac endothelium promoting thrombus formation in the heart. 
Effects of herpesviruses on endothelium and smooth muscle of arteries might predispose to 
arterial dissection or the development of transient cerebral arteriopathy (TCA). Although 
VZV is an established cause of TCA (called “post-varicella arteriopathy” in those cases), the 
role of other herpesviruses could explain why this continues to occur in children vaccinated 
against VZV.
We did not find evidence that past infection with herpesviruses is associated with childhood 
AIS risk. In adults, there has been conflicting evidence that past infection as determined by 
serology is associated with stroke risk. While case-control studies have suggested that 
serologies against certain bacterial and viral pathogens, such as Chlamydia pneumoniae, 
HSV1, and CMV, are associated with stroke risk, prospective cohort studies are less 
convincing.7, 44 Data from the Northern Manhattan Study, however, provide evidence that 
overall infectious burden, using a summative measure of multiple serologies, rather than 
individual pathogens, may be a better marker of risk.45 Our failure to find an association 
with stroke for past herpesvirus infections in children may indicate that the increased risk 
that accumulates over the lifetime has not yet reached a critical point in childhood. 
However, the cases in our study were younger than the controls; hence, we may have missed 
an association between past infection and childhood AIS because the cases had less time to 
acquire an infection.
Our study has additional limitations. First, our pool of controls was restricted to otherwise 
healthy children from whom blood could feasibly be collected. Our choice of children 
evaluated for trauma, while carefully chosen to be as comparable as possible to our cases in 
terms of their likelihood of infection, nonetheless limited the number of potential controls 
available. Because controls were primarily enrolled in the USA, Canada, and Chile, our 
case-control findings are most generalizable to those countries. And although we collected 
convalescent blood samples on cases where possible, our controls did not have parallel 
“convalescent” blood samples. Because single blood samples had low sensitivity for acute 
herpesvirus infection, this likely resulted in some misclassification in our case-control 
analyses. However, the specificity of single blood samples was high, limiting the 
misclassification to false negatives which should bias the association between herpesviruses 
and AIS towards the null. In addition, because we had paired samples in a large subset of 
cases, we had a more accurate estimate of the true prevalence of acute herpesvirus infection 
in the population of interest. Second, cases and controls were not matched by site, and some 
sites were able to contribute only cases. Because childhood stroke is uncommon, enrollment 
of cases required a large number of centers, yet not all could feasibly enroll trauma controls. 
We were able to adjust for SES—which is linked to herpesvirus seroprevalence—and 
perform sensitivity analyses limited to the three countries enrolling the majority of subjects. 
However, there may have been residual confounding related to variables we did not 
measure, or small numbers in important subgroups like LAMI countries. Third, we tested 
blood, but not CSF, for evidence of herpesvirus infection. It is not clear, however, that viral 
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particles need to cross the blood brain barrier for herpesviruses to trigger stroke; the 
pathology could be limited to endothelial injury. Fourth, we cannot be certain that the 
positive serologies detected were not reflective of non-specific immune activation due to 
stroke itself. Immunological activation after stroke is a complex process, and current 
evidence suggests that stroke leads to immunodepression, although individuals with 
concurrent infection may have an increase in immune activation against brain proteins.46, 47 
There is no evidence, however, that antibodies against herpes viruses increase after stroke. 
Finally, serology for herpesviruses can be problematic because of lack of specificity and 
sensitivity of assays as well as differences in individual host response. Because commercial 
IgM ELISA tests are particularly insensitive for VZV, we have likely under-estimated the 
subjects with acute VZV infection; as this misclassification is likely nondifferential 
(affecting cases and controls), we expect it would have biased our results towards the null. 
In addition, serologies alone cannot adequately distinguish between primary versus recurrent 
herpesvirus infection; we will seek additional funding to perform IgG avidity tests to better 
make this distinction.
The strengths of our study are considerable. This is the largest prospective study of 
childhood AIS, a rare and poorly understood condition, and our study represents a 
collaboration of a number of international centers. The potentially inconsistent lab 
procedures, conditions, and interpretation that could result from such diversity was 
anticipated and minimized through use of a central core laboratory to standardize serological 
testing. A protocol which implemented centralized imaging review with a clinical 
adjudication process likewise maximized standardization and consistency in the 
considerable challenge of categorizing stroke and arteriopathy subtypes. Finally, we used 
serological testing in addition to parental interview as a source of information about 
infection.
CONCLUSIONS
Herpesviruses may act as a trigger for childhood AIS. The absence of infectious signs or 
symptoms does not rule out an acute herpesvirus infection, as most children with positive 
acute serologies in our study lacked a history of recent clinical infection. A single acute 
sample is insensitive for detecting herpesvirus infection, so convalescent samples are needed 
to accurately measure infection. Antivirals like acyclovir might have a role in secondary 
stroke prevention strategies, but further evidence in support of a causal role is needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Clinical Perspectives
In this prospective, multicenter study, investigators from the International Pediatric 
Stroke Study consortium found serologic evidence that herpesviruses act as a trigger for 
childhood arterial ischemic stroke. Varicella zoster virus (VZV) is an established cause 
of stroke, known to directly invade the distal internal carotid artery and its major 
branches, and cause a focal vasculitis. It has also recently been implicated as a cause of 
giant cell arteritis. This study suggests a role for other herpesvirus, particularly herpes 
simplex virus type 1 (HSV1). Though cases with stroke were similar to controls in rates 
of past herpesvirus infection, cases were significantly more likely to have an acute 
herpesvirus infection, even after controlling for age and socio-economic status. Among 
cases with serologic analyses of acute and convalescent blood samples, almost half had 
an acute herpesvirus infection, mostly HSV (40% of cases), with fewer cases of VZV, 
cytomegalovirus (CMV), and Epstein Barr virus (EBV). Most had serologies consistent 
with a primary infection, meaning a first-ever infection in a previously seronegative 
child. The majority of acute herpesvirus infections were subclinical, suggesting that a 
negative clinical history cannot rule out herpesvirus infection. A single acute blood 
sample detected fewer than half of the acute herpesvirus infections, suggesting that a 
convalescent blood sample should be tested if an acute sample is negative. Because 
herpesvirus infections are potentially treatable, these findings may have important 
implications for secondary stroke prevention in children, but further evidence in support 
of a causal role is needed.
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Figure 1. 
Flow diagram showing VIPS cases of childhood AIS and trauma-visit controls included in 
the current manuscript. Case-control comparisons are based on assays of the acute blood 
samples in 326 cases and blood samples collected at time of trauma visit for 115 controls; 
collection of convalescent samples in the controls was not feasible. Assays of paired blood 
samples (acute and convalescent) were considered the gold standard for defining positive 
acute herpesvirus serologies amongst cases (as fully described in the methods). Collection of 
convalescent samples in cases was performed when feasible.
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